10-Q: Nordicus Partners Q2 2026: Biotech Portfolio Advances Amid Losses

Nordicus Partners Corporation reported a significant increase in net loss for the six months ended September 30, 2025, as it continues to expand its preclinical biotechnology portfolio and address going concern issues.

Summary

• Net loss for the six months ended September 30, 2025, was $(2,718,360), a substantial increase from $(765,565) for the same period in 2024.
• Cash increased to $242,155 at September 30, 2025, from $19,914 at March 31, 2025.
• Total assets grew to $75,882,821 at September 30, 2025, from $70,246,329 at March 31, 2025.
• Operating expenses significantly increased, with officer compensation up 256% to $350,752 and professional fees up 450% to $396,963 for the six months ended September 30, 2025, compared to 2024.
• Research and development expenses increased by 156% to $878,350 for the six months ended September 30, 2025, primarily due to Bio-Convert.
• The company acquired a 50.01% ownership interest in NoviThera ApS in October 2025, expanding its preclinical biotechnology portfolio to three companies.
• Orocidin A/S successfully completed a 14-day toxicology study in hamsters and a Beagle Dog Study, showing high drug tolerance and a direct effect on periodontitis.
• Bio-Convert A/S received positive scientific advice from the Danish Medicines Agency (DKMA) for its lead candidate, QR-02, potentially allowing for First in Human trials without animal studies.
• Raised $618,750 in gross proceeds from private investors in October 2025 by issuing 225,000 restricted shares at $2.75 per share.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Sentiment

Score: 4

Explanation: While there are positive developments in the preclinical pipeline and successful capital raises, the significant increase in net loss, the explicit 'going concern' warning, and the ineffective disclosure controls indicate substantial financial and operational challenges. The positive R&D news is offset by the company's precarious financial position and reliance on future capital raises.

Positives

• Cash position significantly increased to $242,155 at September 30, 2025, from $19,914 at March 31, 2025.
• Orocidin A/S successfully completed a 14-day toxicology study in hamsters, demonstrating high drug tolerance with no adverse reactions or irritation.
• Orocidin A/S's Beagle Dog Study showed QR-01 having a direct effect on periodontitis, with consistent improvements across key clinical endpoints.
• Bio-Convert A/S received positive and constructive scientific advice from the Danish Medicines Agency (DKMA) for QR-02, potentially allowing for First in Human trials without animal studies.
• Expanded the life sciences portfolio with the formation and acquisition of a 50.01% ownership interest in NoviThera ApS in October 2025, focusing on psoriasis treatment.
• Successfully raised $618,750 in gross proceeds from private investors in October 2025 through the issuance of 225,000 restricted shares of common stock.

Negatives

• Net loss significantly increased to $(2,718,360) for the six months ended September 30, 2025, compared to $(765,565) in the prior year period.
• Accumulated deficit reached $49,503,208 as of September 30, 2025.
• Loss from operations for the six months ended September 30, 2025, was $(2,043,364), a substantial increase from $(765,564) in the prior year.
• Operating expenses increased substantially, with officer compensation up 256% and professional fees up 450% for the six months ended September 30, 2025.
• Recorded a $675,000 loss from changes in the fair value of its investment in Mag Mile Capital, Inc. for the six months ended September 30, 2025.
• Foreign currency translation adjustment resulted in a loss of $(228,975) for the three months ended September 30, 2025.
• The company's current funds are not sufficient to meet its needs for more than twelve months, indicating substantial doubt about its ability to continue as a going concern.
• Disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Risks

• Substantial doubt about the ability to continue as a going concern due to nominal revenue and accumulated losses of $49,503,208.
• Dependence on generating profitable operations in the future and/or obtaining necessary financing to meet obligations and repay liabilities.
• Uncertainty regarding the results of research and development, clinical testing, and trial activities of the company's products.
• Ability to obtain regulatory approval to market its products.
• Competition from products manufactured and sold or being developed by other companies.
• Ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.
• Ability to raise capital.
• Disclosure controls and procedures were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions, posing risks to financial reporting accuracy.

Future Outlook

Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock. The company aims to take all portfolio companies' drug developments through Phase I. Upon completion of Phase I, the company will consider options such as sale or merger of the portfolio company, further development through next clinical phases, strategic partnership with a large pharmaceutical company, or a stand-alone Initial Public Offering (IPO). The company is evaluating the impact of new accounting standards on income tax disclosures and expense disaggregation, with anticipated reflection in its annual financial statements for the year ended March 31, 2026, and fiscal years beginning after December 15, 2026, respectively.

Management Comments

• "The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws."
• "Nordicus mission is to back high-growth ventures and transformative innovations in the life sciences sector."
• "Nordicus portfolio diversification strategy positions us as a stable and resilient company, mitigating risk with significant upside potential."
• "The Company's current funds will not be sufficient to meet its needs for more than twelve months from the date of issuance of these unaudited condensed consolidated financial statements."
• "Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock."
• "Our chief executive and financial officer concluded that our disclosure controls and procedures as of September 30, 2025, were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions."

Industry Context

Nordicus Partners operates as a business accelerator and holding company focused on bringing Nordic life sciences innovations to the American market. This strategy positions it within the high-growth, high-risk biotechnology sector, particularly in preclinical drug development for unmet medical needs like periodontitis, oral leukoplakia, and psoriasis. The company's approach of acquiring controlling stakes and providing operational expertise aims to de-risk early-stage ventures, a common model in biotech where capital and specialized guidance are crucial for advancing drug candidates through clinical phases. The focus on oral formulations with prolonged adhesion and controlled release represents a competitive advantage in drug delivery.

Comparison to Industry Standards

• The company's preclinical stage for all three portfolio companies (Orocidin A/S, Bio-Convert A/S, NoviThera ApS) is typical for early-stage biotech firms, which inherently carry high development risk and require significant capital.
• The successful completion of a 14-day toxicology study and a Beagle Dog Study for Orocidin A/S's QR-01 is a positive step, comparable to early animal model testing in drug development, but still far from human clinical trials and market approval.
• Bio-Convert A/S receiving positive scientific advice from the Danish Medicines Agency (DKMA) regarding QR-02, potentially bypassing animal studies for First in Human trials, could accelerate its development timeline compared to typical drug candidates that require extensive preclinical animal testing.
• The formation of NoviThera ApS to develop a novel Monoclonal antibody for psoriasis aligns with a competitive and active area of research in immunology, where several large pharmaceutical companies (e.g., AbbVie with Humira, Novartis with Cosentyx, Eli Lilly with Taltz) have established products, indicating a large market but also significant competition.
• The substantial accumulated deficit of $49.5 million and the 'going concern' warning are common for preclinical biotech companies that are pre-revenue and heavily investing in R&D, but it highlights a critical financial vulnerability compared to more established industry players.

Management Changes

Corporate Governance

Legal Proceedings

• Not the subject of any pending legal proceedings, and no proceedings are presently contemplated against the company by any federal, state, or local governmental agency.
• No director or executive officer is party to any action in which any has an interest adverse to the company.

Related Party Transactions

• GK Partners ApS, affiliated with former director Tom Glaesner Larsen, was involved in the acquisition of Mag Mile Capital equity interests and exercised warrants.
• GK Partners purchased 49,000 shares of the company's common stock at a price of $5.00 per share for gross proceeds of $245,000 during the six months ended September 30, 2025.
• Mr. Bennett Yankowitz, CFO and director, is affiliated with legal counsel (the Affiliate) who provided legal services, resulting in fees of $16,492 for the six months ended September 30, 2025.
• Henrik Rouf, CEO, and Bennett Yankowitz, CFO, had their annual salaries increased to $360,000 and $120,000 respectively, and their employment terms extended to July 1, 2026.
• Darlington Group, LLC, controlled by new director Andrew Ritter, entered into a consulting agreement on October 1, 2025, for $10,000 per quarter for strategic guidance and operational support.

Stakeholder Impact

• Shareholders face significant dilution from past stock issuances (weighted average shares outstanding increased to 17.5M for 6 months ended Sep 30, 2025, from 4.0M in prior year) and potential future dilution from capital raises.
• A share repurchase program was authorized for up to 200,000 shares, with 57,642 shares repurchased post-period, which could benefit participating shareholders.
• The explicit "going concern" warning poses a significant risk to the investment value for all shareholders.
• Executive salaries increased significantly, and new board members received stock options, indicating continued investment in leadership despite company losses.
• The "going concern" warning suggests increased credit risk for potential and existing creditors.

Next Steps

• Conduct an upcoming pivotal 8-week toxicity study for Orocidin A/S's QR-01.
• Prepare for a human pilot efficacy study for Orocidin A/S's QR-01.
• Advance Bio-Convert A/S's QR-02 towards a First in Human trial.
• Develop a human rat model for NoviThera ApS's psoriasis treatment and test it in other relevant animal disease models.
• Management intends to finance operating costs through private placements of Common Stock.
• Remediate deficiencies in disclosure controls and procedures.
• Consider options for portfolio companies after Phase I completion: sale/merger, further clinical development, strategic partnership, or stand-alone IPO.

Key Dates

Recommendation

The company faces significant financial distress, evidenced by a substantial increase in net loss, a large accumulated deficit, and an explicit 'going concern' warning. While there are positive preclinical developments and recent capital raises, these are insufficient to offset the fundamental liquidity and profitability challenges. The ineffective disclosure controls further raise concerns about financial transparency and risk management. A seasoned investor would likely view the current financial position as highly speculative and recommend selling to mitigate further downside risk, despite the long-term potential of its biotech pipeline.

Keywords

biotechnology, life sciences, preclinical, periodontitis, oral leukoplakia, psoriasis, drug development, Nordic innovation, business accelerator, SEC filing, 10-Q, Nordicus Partners